WeVote
Log In

Bill

Bill

A 4296

Limits the off label use of antipsychotic drugs on elderly patients with dementia

2025 Regular Session Introduced by Alicia Hyndman

Limits off-label antipsychotic use in elderly dementia patients, aiming to improve safety and oversight for prescribers, facilities, and insurers.

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · A 4296

Summary of Assembly Bill A 4296

Overview

A 4296 is an introduced bill in the New York Assembly aimed at limiting the off-label use of antipsychotic drugs in elderly patients with dementia. The bill was introduced on February 4, 2025, and as of the latest legislative actions, has been referred to the Health Committee.

Purpose and Intent

  • The primary objective is to restrict or regulate the off-label prescribing of antipsychotic medications for elderly individuals with dementia.
  • The underlying intent appears to address safety and quality of care concerns associated with antipsychotic use in this population.

Key Provisions (Based on Title)

  • The specific statutory provisions, definitions, exemptions, enforcement mechanisms, and penalties are not provided in the available information.
  • What is clear from the bill’s title is a focus on limiting off-label use of antipsychotics for seniors with dementia, which could imply new prescribing guidelines, oversight requirements, or restrictions applicable to healthcare providers and facilities.

Note: Without the bill text, concrete details such as patient protections, clinician exemptions, reporting obligations, timelines for compliance, or penalties cannot be confirmed here.

Who Would Be Affected

  • Elderly patients diagnosed with dementia who are current or potential recipients of antipsychotic medications.
  • Healthcare providers who prescribe antipsychotics to dementia patients (physicians, psychiatrists, geriatricians, etc.).
  • Long-term care facilities, hospitals, and pharmacies involved in the prescribing, dispensing, or administration of antipsychotic drugs to this population.
  • Payers/insurers involved in coverage and monitoring of antipsychotic prescriptions.

Procedural and Timeline Details

  • Introduced: February 4, 2025.
  • Status: REFERRED TO HEALTH.
  • Legislative actions show two entries on the same date indicating the bill was referred to the Health Committee; no further actions are listed in the provided record.

Sponsorship

  • Primary sponsor: Alicia Hyndman.

Related Legislation

  • A 8212 (prior-session)
  • A 3374 (prior-session)
  • S 4380 (companion) — listed as a companion bill, appears twice in the record, indicating cross-chamber or parallel tracking.

Potential Impact (General)

  • If enacted, the bill could modify prescribing practices for antipsychotics in dementia patients and potentially introduce new oversight, reporting, or compliance requirements for providers and facilities.
  • Could influence patient safety outcomes by reducing inappropriate or off-label use, while also affecting care strategies for managing behavioral and psychological symptoms of dementia.
  • The absence of the bill text limits assessment of exemptions, enforcement, and cost implications.

Next Steps

  • Review the full bill language for precise provisions, including definitions, exceptions, penalties, enforcement, and effective dates.
  • Monitor committee action in Health and any floor votes in the Assembly, as well as any companion Senate action (S 4380) for a complete picture of progression.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.